Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein pseudogenes, such as ENSG00000220370, are DNA sequences in the human genome originally derived from ribosomal protein genes (in this case, RPL7A). Over evolutionary time, these sequences have accumulated disabling mutations, truncations, or rearrangements, and thus do not code for functional ribosomal proteins. While most pseudogenes are nonfunctional remnants, some are transcribed and may produce RNA or short peptides, but such products typically lack canonical ribosomal or regulatory function. Only a small fraction of ribosomal protein pseudogenes are transcriptionally or translationally active, and their roles, if any, are not well characterized. This particular pseudogene is not considered a drug target nor is it associated with any established physiological or pathological function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L7A pseudogene (RPL7A pseudogene).